A Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome: Influence on Neurohormonal Activation and Clinical Outcomes

Journal of Cardiac Failure

Volumn 15, Issue 9, 2009, Pages 727-735

  Comín Colet, Josep ^a,b   Ruiz, Sonia ^a   Cladellas, Mercè ^a,b   Rizzo, Marcelo ^a   Torres, Adriana ^a   Bruguera, Jordi ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Anemia; chronic heart failure; chronic renal failure; erythropoietin; intravenous iron; natriuretic peptides

Indexed keywords

CREATININE; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; NATRIURETIC FACTOR;

AGED; ANEMIA; ARTICLE; CARDIORENAL ANEMIA SYNDROME; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CRUSH SYNDROME; DISEASE SEVERITY; DRUG ACTIVITY; ELDERLY CARE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL REGULATION; HOSPITALIZATION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; DRUG EVALUATION; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; NEUROTRANSMITTER AGENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350567772     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.05.010     Document Type: Article

References (31)

1. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
2. Metra M., Ponikowski P., Dickstein K., McMurray J.J., Gavazzi A., Bergh C.H., et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9 (2007) 684-694
3. Silverberg D.S., Wexler D., Blum M., Wollman Y., Schwartz D., Sheps D., et al. The interaction between heart failure, renal failure and anemia-the cardio-renal anemia syndrome. Blood Purif 22 (2004) 277-284
4. Groenveld H.F., Januzzi J.L., Damman K., van Wijngaarden J., Hillege H.L., van Veldhuisen D.J., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52 (2008) 818-827
5. Anand I., McMurray J.J.V., Whitmore J., Warren M., Pham A., McCamish M.A., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
6. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes-insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107 (2003) 223-225
7. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
8. Opasich C., Cazzola M., Scelsi L., De Feo S., Bosimini E., Lagioia R., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26 (2005) 2232-2237
9. Mancini D.M., and Kunavarapu C. Effect of erythropoietin on exercise capacity in anemic patients with advanced heart failure. Kidney Int 64 (2003) S48-S52
10. Bolger A.P., Bartlett F.R., Penston H.S., O'Leary J., Pollock N., Kaprielian R., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1225-1227
11. Ghali J.K., Anand I.S., Abraham W.T., Fonarow G.C., Greenberg B., Krum H., et al. on behalf of the Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation 117 (2008) 526-535
12. Okonko D.O., Grzeslo A., Witkowski T., Mandal A.K.J., Slater R.M., Roughton M., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol 51 (2008) 103-112
13. Palazzuoli A., Silverberg D., Iovine F., Capobianco S., Giannotti G., Calabro A., et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 (2006) 6
14. Ponikowski P., Anker S.D., Szachniewicz J., Okonko D., Ledwidge M., Zymlmski R., et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure-a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49 (2007) 753-762
15. Toblli J.E., Lombrana A., Duarte P., and Di Germaro F. Intravenous iron reduces NT-Pro-Brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007) 1657-1665
16. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., Lok D.J., Wasserman S.M., Baker N., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28 (2007) 2208-2216
17. Van der M.P., Groenveld H., Januzzi J.L., and van Veldhuisen D.J. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart (2009 January) [Epub ahead of print]
18. Silverberg D.S., Wexler D., Blum M., Schwartz D., Keren G., Sheps D., et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Israel Med Assoc J 5 (2003) 337-339
19. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
20. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
21. van der Meer P., Lipsic E., Westenbrink B.D., van de Wal R.M.A., Schoemaker R.G., Vellenga E., et al. Levels of Hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112 (2005) 1743-1747
22. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
23. Jaarsma T., Stromberg A., Martensson J., and Dracup K. Development and testing of the European Heart Failure Self-Care Behaviour Scale. Eur J Heart Fail 5 (2003) 363-370
24. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
25. O'Meara E., Chong K.S., Gardner R.S., Jardine A.G., Neilly J.B., and McDonagh T.A. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Failure 8 (2006) 63-67
26. Kirk V., Bay M., Parner J., Krogsgaard K., Herzog T.M., Boesgaard S., et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6 (2004) 335-341
27. Bailie G.R., Clark J.A., Lane C.E., and Lane P.L. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20 (2005) 1443-1449
28. Kulnigg S., Stoinov S., Simanenkov V., Dudar L.V., Karnafel W., Garcia L.C., et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 103 (2008) 1182-1192
29. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 (2007) 381-388
30. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int 75 (2008) 358-365
31. Streja E., Kovesdy C.P., Greenland S., Kopple J.D., McAllister C.J., Nissenson A.R., et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736